Buzz
When Pfizer’s COVID-19 vaccine received approval in August, it was specifically authorized for individuals aged 16 and older as a two-dose regimen. Although fully-approved medications and vaccines can be used off-label, many began questioning whether healthcare providers could administer the vaccine to younger children or offer booster shots to those outside the approved criteria. However, this scenario is unlikely due to specific regulatory constraints. To understand why, let’s first explore the concept of off-label use.
Understanding the Term 'Off Label'
Medications and vaccines receive FDA approval for specific uses, but healthcare providers have the discretion to prescribe them for other purposes. For instance, a chemotherapy drug approved for one type of cancer might be prescribed for another. The FDA highlights this in their explanation of off-label use, noting that such practices may occur when no approved treatment exists for a condition or when standard treatments have proven ineffective.
In theory, healthcare providers could administer a vaccine to an age group or for a purpose outside its approved use. While this practice would be legally permissible, it is not advisable.
What Sets the COVID Vaccine Apart
The distribution of COVID vaccines in the U.S. differs significantly from most other vaccines or medications. The federal government purchased all vaccine doses, rather than allowing providers to order them directly. Providers must adhere to the terms of the CDC COVID-19 Vaccination Program, which mandates administering vaccines only as recommended.
If a provider administers the vaccine off-label, they risk being removed from the program and losing the ability to distribute future doses. Additionally, they may no longer be protected under the Public Readiness and Emergency Preparedness Act (PREP Act), which shields them from liability in case of adverse outcomes.
From the patient’s perspective, there are also drawbacks, as outlined by the CDC here. For instance, insurance might refuse to cover the administration fee, leaving patients or parents responsible for the cost. Furthermore, individuals experiencing adverse effects from the vaccine would not qualify for compensation, unlike with other vaccine-related injuries.
The American Academy of Pediatrics also discourages off-label use for children, emphasizing that the doses tested in pediatric vaccine trials differ from those for adults, and safety data for children remains insufficient. Pfizer anticipates seeking emergency authorization for ages 5 to 11 by late September, so the wait may not be long. For those awaiting boosters, legal distribution could begin as early as Sept. 20, so patience is key.
